LATEST NEWS AND EVENTS
The Rising Role of Radiotheranostics
Recent Research and Developments have brought forward the pivotal role of radiotheranostics for cancer care. Whether you refer to them as Radiotheranostics, Theranostics, Theragnostics, Radioligand [...]
Lu-177-PSMA-617A Added to Standard Therapy
VISION Trail Results Indicate Benefit of 177Lu-PSMA-617A Added to Standard Therapy, Cancer Network, Jason M. Broderick, June 3, 2021 A 40% reduction in the risk [...]
Theranostic Approach in Breast Cancer
Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology, PubMed.gov, Clin Nucl Med, 2021 Aug 1 Review on current status of preclinical and [...]
FDA for Lu-177-PSMA-617 for mCRPC treatment
Targeted Oncology, Sarah Karlovitch, June 17, 2021 The FDA has granted breakthrough therapy designation to 177Lu-PSMA-617, an investigational radioligand therapy for the treatment of metastatic [...]
Global Nuclear Medicine Market 2013-2025
Key slide by MEDraysintell used at the SNMMI virtual meeting 2021 to show the anticipated impact of radiotheranostics. As mentioned by our US Ambassador Jean-Luc [...]
Drugmakers push into radio pharmaceuticals
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 (2021). Radiotheranostics Tsunami! Interesting recent read about the growing clinical and financial interest in radiopharmaceuticals [...]
NOBLE: Tc-99m-iPSMA SPECT shows promising results
Promising results following the initial experience using Tc-99m-iPSMA led by Dr. Yehia Omar within the Noble Registry. Prostatic lesions, nodal and bony deposits in a single exam on [...]
Asco 2021 justifies Novartis’s radioligand Vision
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase [...]
Theranostics: Reimagining the standard of care
HealthCare Business News magazine, June 2021, Tiffany Olson It may be one of the most elusive questions in all of medicine: How can healthcare providers [...]
EANM position paper on the role of radiobiology in nuclear medicine
Aerts, A., Eberlein, U., Holm, S. et al. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging [...]
Travel cards could help radiopharma patients avoid delays
April 29, 2020 -- Patients who undergo radiation treatment with lutetium-177 (Lu-177)-DOTATATE for neuroendocrine tumors should receive and carry a travel card with details of their [...]
PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC
Urology Times Journal, Jason M. Broderick - April 15, 2021 The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 (LuPSMA) is rapidly advancing through the pipeline in metastatic castration-resistant prostate [...]
Noble Registry – iPSMA SPECT Imaging for Prostate Cancer
BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – The Oncidium foundation, a non-profit organisation created to promote and support the development of radiopharmaceuticals [...]
Doctor, What is Neuroendocrine Cancer?
Waiting for a download is frustrating. Imagine waiting 5+ years for a cancer diagnosis. Neuroendocrine cancer takes on average 5+ years to diagnose due to [...]
How Nuclear Technology can Beat Cancer
How nuclear medicine can beat cancer? These are extraordinary times, and patients waiting for life-changing medical treatments should not suffer. They want to know that [...]
Seeing Cancer Cells, Killing Cancer Cells
Using molecules to safely carry radioactive materials inside the human body is helping physicians get more accurate images of tumors and more effectively eliminate cancer [...]
Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC
225Ac-PSMA RLT is an efficacious and safe treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Future randomized controlled trials are required to establish [...]
World Theranostics Day 2021!
Today is World Theranostics Day! On this day in 1941, the first radioiodine treatment was administered and we are very eager to see what's yet [...]
How PRRT can Improve Care for Neuroendocrine Tumor Patients
Learn more about how Peptide Receptor Radionuclide Therapy (PRRT) can improve care for Neuroendocrine Tumor patients. Another effective illustration of how Radiotheranostics work and its [...]
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
With some radiopharmaceuticals now used in clinical practice, somatostatin analogs developed for imaging and therapy are an example of the concept of personalized medicine with [...]
Real-world data analysis of efficacy and survival after Lu-177 PSMA in metastatic castration-resistant prostate cancer
177Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph node [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant prostate cancer (mCRPCC) with the beta-emitter Lutetium-177 has had several early-stage dosimetry studies published, demonstrated [...]
What is in the pipeline for nuclear medicine, globally?
In recent years, the nuclear medicine market has undergone many changes. The medical specialty, not well known to the general public, is gaining more and [...]
Oncidium foundation welcomes it’s Turkish Ambassador, Mr. Hasan Ulaş Özcan
Welcome Mr. Hasan Ulaş Özcan as an Oncidium foundation Ambassador in Turkey. Our mission is to support & promote the development of Radiotheranostics globally. Thus, [...]
Oncidium foundation is a corporate member of the SNMMI Value Initiative
The Oncidium foundation is a corporate member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Value Initiative program to advance the crucial role [...]
Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model
Joint radionuclide therapy and immunotherapy approach. The combination shows promising therapeutic option for prostate cancer patients. Read full article >>
The Winter Newsletter is out!
Looking back at 2020 accomplishments, fundraising campaign, meeting the newcomers Ambassadors, focusing on the latest developments in the Radiotheranostics field and meeting Tom, neuroendocrine cancer [...]
World Cancer Day 2021
Today, the Oncidium foundation unites its voice with the World Cancer Day! No matter who we are or where we live, this occasion is a [...]
Hopeful 2021!
This year has shown us more than ever the importance of access, education & hope. We've adapted to new normal & witnessed once again the developments [...]
New Theranostic Approach reduces tumor volume and increases survival in NET’s study
Axis - Dec 16, 2020 According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality [...]
Another achievement to bring Radiotheranostics forward
300 hospitals registered on the Oncidium foundation Map! Another achievement to bring Radiotheranostics forward and strive for access education and hope. Thank you to all [...]
NET Patient Testimonial, how PRRT saved Tom’s life
Tom is a composer, pianist, audio producer and neuroendocrine tumor patient. When he was diagnosed with NET's, he didn't know that PRRT could save his life [...]
Diagnostic accuracy of 18 F-PSMA-1007-PET/CT imaging for prostate carcinoma
J. Nucl. Me. 2020 Aug 17 18F-PSMA-1007-PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of >99% for nodal metastases. Congratulations for this [...]
Radiopharmaceuticals Emerging as New Cancer Therapy
National cancer Institute. October 26, 2020 The last years have seen an explosion of research and clinical trials testing new radiopharmaceuticals suggesting that targeting radiation [...]
October Rose – Breast Cancer Awareness Month
The Oncidium foundation wears the colors of October Rose. Breast Cancer is by far the most common cancer in women worldwide, both in developed and [...]
Nuclear Medicine and Molecular Imaging Week: October 4-10, 2020
October 4-10 2020 is nuclear medicine and molecular imaging week! A great initiative by Society of Nuclear Medicine and Molecular Imaging (SNMMI) to raise awareness [...]
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced metastatic castration resistant prostate cancer patients: promising antitumor effect in advanced mCRPC even [...]
IAEA activities on Cu-67, Re-186, Sc-47 Theranostic radionuclides and Radiopharmaceuticals
International Atomic Energy Agency (IAEA) activities on 67Cu, 186Re, 47Sc Theranostic radionuclides and Radiopharmaceuticals: Extraordinary results on the production, quality control and preclinical evaluation of [...]
The Role of Ga-68-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract (LGT): First Clinical Experience seems to be a highly promising imaging [...]
Cancer awareness month – September, don’t forget to remember
The month of September represents the prostate cancer, thyroid cancer, leukemia and lymphoma, and female cancer awareness month. Thus, an important way of supporting and [...]
First patients dosed in clinical trial of novel lung and ovarian cancer theranostic
Telix Pharmaceuticals Limited announced that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer theranostic [...]
Sirtex Medical and China Grand Pharmaceutical announce landmark drug registration milestone
Sirtex Medical (“Sirtex”) is a leading manufacturer of targeted liver cancer therapies. It announced today that Sirtex and its shareholders have been issued a “Notice [...]
Efficacy and safety of 225 Ac-PSMA-617 TAT in Prostate Cancer
PubMed, July 23, 2020 Despite the success of several standards of care treatment options in metastatic castration-resistant prostate cancer (mCRPC), a significant number of patients [...]
Astatine is a chemistry puzzle that shows anticancer promise
c&en, chemical & engineering news, august 13, 2020. Astatine is the rarest naturally occurring element on Earth. It resists easy chemical classification. In reactions, it [...]
This is not a simple flower, this is an Oncidium
Ever wondered the meaning behind the name and logo of the Oncidium foundation? This is not a flower, this is an Oncidium. A kind of [...]
Webinar Theranostics and PET Imaging Diagnostics
Webinar Theranostics and PET Imaging Diagnostics by IBA RadioPharma Solutions Watch this instructive webinar on the use of PET radiopharmaceuticals in Theranostic applications. Learn more [...]
Theranostics continue to gain momentum
Article by Richard Zimmermann, President & Founder of the Oncidium foundation. Radiotheranostics are molecules that can safely carry radioactive isotopes inside targeted human tissues and [...]
In memory of Sanjiv Sam Gambhir, a leader in the development of precision oncology
Molecular imaging pioneer Sanjiv Sam Gambhir, MD, PhD, passed away on Saturday, July 18, from cancer. He was 57. From the earliest days of his [...]
Another milestone for the Oncidium foundation
Another milestone for the Oncidium foundation: 200 registered hospitals and counting! Thank you to all the nuclear medicine experts that registered their treatment center using [...]
The Oncidium foundation supports the SVIMS
In India, the Sri Venkateswara Institute of Medical Sciences (SVIMS), is a University Hospital based in Tirupati. The city is home to most famous and [...]
Atomic Nanogenerators in Targeted Alpha Therapy
Atomic in vivo nanogenerators such as actinium-225, thorium-227, and radium-223 are of increasing interest and importance in Targeted Alpha Therapy (TAT), in the treatment of [...]
Postponing PRRT treatment during COVID 19
Postponing PRRT in Neuroendocrine tumors during COVID-19. What do you think? Check out the interesting responses of experts in the field. Read more >>
ProsTIC – The new Centre of Excellence
Congratulations Peter MacCallum Cancer Centre for the launch of The Prostate Theranostics & Imaging Centre of Excellence. ProsTIC will lead state-of-the-art research to deliver new prostate [...]
Prostate Cancer Theranostics – An Overview
The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized clinically [...]
TheraP Trial Design in Prostate Cancer
Interesting interview with Pr. Michael Hofman about TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer, where results are expected [...]
Oncidium Spring NEWSLETTER
Fresh news about Oncidium and Radiotheranostics, close up on Neuroendocrine Cancer UK, meet the Oncidium Ambassadors and much more! >> Discover the Newsletter
Covid19 – Stay safe
Today, we would like to raise awareness of a different nature, equally important. We hope your relatives and you are well and healthy. The health [...]
The Oncidium foundation goes live !
After six months of hard labor, research and discussions, welcome to the Oncidium’s new website! The entire website has been face-lifted in a user-friendly way [...]
World Cancer Day
The 4th of February is the World Cancer Day. Let's increase opportunities to build global awareness and impact-driven action. Keep strong, keep believing, keep going. [...]
Radiolabeled PSMA PET for Renal Cancer
Promising results regarding the role of Radiolabeled PSMA PET as an imaging modality for the evaluation of widespread disease and response to target and local [...]
How Radiotheranostics work?
Still wondering how Radiotheranostics work? Read this very interesting and accessible article by the International Atomic Energy Agency (IAEA):“It is a very efficient approach that [...]
Strong potential of targeted α-therapy with 225Ac-PSMA-617
Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. Dr. Machaba Michael Sathekge comments the initial [...]
Merry Christmas and Happy New Year
What a year! Looking back at 2019, we were able to start The Oncidium foundation activities, build a motivated team, meet wonderful dedicated people from [...]
Happy Thanksgiving
This year, Oncidium has a lot to be thankful for! We have been able to start our activities around the promotion of Radiotheranostics. First and [...]
Promising results for prostate cancer response to PRLT
First promising results on a pilot experience suggest that a single course of tandem therapy with low-activity 225Ac-PSMA-617/full-activity 177Lu-PSMA-617 may safely enhance response to PRLT [...]
A dedicated Oncidium’s Ambassador at ALASBIMN 2019
We could not have missed the XXVII Congress of ALASBIMN 2019 in Lima, Peru! Such an important congress at the regional level that brings great [...]
EANM commitment: learning from the UK experience
Patient/public involvement and engagement (PPI/PE) incorporates and integrates individual’s perspectives in the planning and improvement of healthcare services and research: “No matter how complicated the [...]
CONNECT WITH US
he Rising Role of #Radiotheranostics supported by the #Oncidiumfoundation. Discover and share our article published in the SNMMI Value Initiative Newsletter on how #Theranostics are here to stay with already approved products and more on the way.
https://t.co/UnzayBBIXz https://t.co/UvMajBmZId
New #hope for #HepatocellularCarcinoma ( #HCC) detection. Study comparing the diagnostic performances of Ga-68-FAPI-04 PET/CT and F-18-FDG PET/CT.
#imagingtechnologies #diagnosis #tracer #nuclearmedicine #precisiononcology #fapi
https://t.co/1LpskgCDmN
Interesting new paper on the safety/toxicity of #LuSMA in the multicenter phase 2 trial RESIST-PC NCT03042312
#PSMA #theranostics #prostatecancer #hope #radioligandtherapy #cancertreatment #mCRPC #safety https://t.co/BkxR6tEq3c
Read the case study on Ga-68-PSMA-11 PET/CT #imagingtechnologies in patients with recurrent #prostatecancer #mCRPC presented by
@TelixPharma and @GenesisCare.
#PSMA #theranostics #radiopharmaceuticals #precisiononcology #cancerdiagnosis https://t.co/ac3Q4cJEKQ
With Prof. Nat Lenzo @GenesisCare, Telix is pleased to present a case study on 68Ga-PSMA-11 PET/CT imaging in patients with recurrent #ProstateCancer:
https://t.co/HlwimKnhYj
Visit our dedicated @Applied_Rad page for more clinical cases and Telix news:
https://t.co/NZTfViDSPC https://t.co/DvNIdP1AQi